Management of Hormonal Contraceptives for Acne and Hyperandrogenism

Contraceptive Selection

The American Academy of Dermatology recommends switching from the transdermal contraceptive patch to a combined oral contraceptive containing cyproterone acetate 2mg/ethinyl estradiol 35μg, or if unavailable, use drospirenone 3mg/ethinyl estradiol 30μg or norgestimate/ethinyl estradiol 35μg, due to their superior anti-androgenic properties for treating acne and elevated androgens 1
Combined oral contraceptives are FDA-approved for acne treatment in women who also desire contraception, with four specific formulations approved: ethinyl estradiol/norgestimate, ethinyl estradiol/norethindrone acetate/ferrous fumarate, ethinyl estradiol/drospirenone, and ethinyl estradiol/drospirenone/levomefolate 1

Before changing contraceptive methods, complete a hormonal workup, including measuring free and total testosterone, DHEA-S, androstenedione, LH, and FSH to evaluate for polycystic ovary syndrome (PCOS) or other hyperandrogenic conditions 2
Assess for PCOS criteria: hyperandrogenism (clinical or biochemical) plus persistent oligomenorrhea in adolescents 2
Monitor blood pressure at follow-up visits, though routine follow-up is not required for healthy adolescents on COCs 7, 8

Combine a topical retinoid with benzoyl peroxide for mixed comedonal and inflammatory acne, as combination therapy addressing multiple pathogenic factors is recommended for most acne patients 2
Topical dapsone 5% gel is specifically recommended for inflammatory acne in adult females 2
Avoid topical antibiotics as monotherapy due to bacterial resistance risk; always combine with benzoyl peroxide if using antibiotics 2

COCs typically require 3-6 months to show significant improvement in acne, as hormonal effects on sebaceous glands take time to manifest 1
Assess thrombotic risk factors before prescribing COCs, as they increase VTE risk 3-4 fold, though this remains lower than pregnancy-associated VTE risk 6
The patch carries a potentially increased VTE risk (odds ratios 1.2-2.2) compared to lower-dose oral contraceptives 3, 4, 5